Will Novo Nordisk’s Bold Pivot to China Reshape Global Pharma?
Novo Nordisk is expanding beyond diabetes and obesity treatments, exploring new markets and technologies. The company is increasingly partnering with Chinese firms, benefiting from rapid innovation and cost-effective processes. Approximately one-third of major pharmaceutical deals now involve collaborations with Chinese companies, challenging
